spironolactone has been researched along with Hypertension, Malignant in 12 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
Hypertension, Malignant: A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant hypertension was induced with dietary indole-3-carbinol (0." | 5.34 | Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. ( Graciano, ML; Mitchell, KD; Mullins, JJ; Ortiz, RM, 2007) |
| "Malignant hypertension was induced with dietary indole-3-carbinol (0." | 1.34 | Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats. ( Graciano, ML; Mitchell, KD; Mullins, JJ; Ortiz, RM, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villafuerte Ledesma, HM | 1 |
| Peña Porta, JM | 1 |
| Iñigo Gil, P | 1 |
| Martin Azara, P | 1 |
| Ruiz Lalglesia, JE | 1 |
| Tomás LaTorre, A | 1 |
| Martínez Burillo, A | 1 |
| Vernet Perna, P | 1 |
| Álvarez Lipe, R | 1 |
| Takahashi, F | 1 |
| Goto, M | 1 |
| Wada, Y | 1 |
| Hasebe, N | 1 |
| SAMBHI, MP | 1 |
| BECK, JC | 1 |
| VENNING, EH | 1 |
| HOFFMEISTER, W | 1 |
| Ortiz, RM | 1 |
| Graciano, ML | 1 |
| Mullins, JJ | 1 |
| Mitchell, KD | 1 |
| Takahashi, T | 1 |
| Ono, H | 1 |
| Ono, Y | 1 |
| Ishimitsu, T | 1 |
| Matsuoka, H | 1 |
| Moyer, JH | 1 |
| Baglin, A | 2 |
| Weiss, Y | 1 |
| Safar, M | 2 |
| Milliez, P | 2 |
| Kim, KE | 1 |
| Onesti, G | 1 |
| Swartz, C | 1 |
| Olbing, H | 1 |
| Greifer, I | 1 |
| Bennett, BP | 1 |
| Bernstein, J | 1 |
| Spitzer, A | 1 |
| Froment, R | 1 |
| Froment, A | 1 |
| Zech, P | 1 |
1 review available for spironolactone and Hypertension, Malignant
| Article | Year |
|---|---|
Drug systems approach to hypertension.
Topics: Captopril; Clonidine; Drug Combinations; Drug Therapy, Combination; Guanethidine; Humans; Hydralazin | 1984 |
11 other studies available for spironolactone and Hypertension, Malignant
| Article | Year |
|---|---|
Severe renal failure and thrombotic microangiopathy induced by malignant hypertension successfully treated with spironolactone.
Topics: Adult; Humans; Hypertension, Malignant; Male; Remission Induction; Renal Insufficiency; Severity of | 2018 |
Successful Treatment with an Antihypertensive Drug Regimen Including Eplerenone in a Patient with Malignant Phase Hypertension with Renal Failure.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Cal | 2015 |
MALIGNANT HYPERTENSION AND ALDOSTERONE SECRETION. INFLUENCE OF REVERSAL AND PROGRESSION OF THE SYNDROME IN TWO CASES.
Topics: Aldosterone; Humans; Hyperaldosteronism; Hypertension; Hypertension, Malignant; Spironolactone; Urem | 1963 |
[PATHOPHYSIOLOGY AND CLINICAL ASPECTS OF SECONDARY ALDOSTERONISM AND ITS TREATMENT].
Topics: Adrenocorticotropic Hormone; Aldosterone; Ascites; Body Fluids; Classification; Dexamethasone; Extra | 1964 |
Aldosterone receptor antagonism alleviates proteinuria, but not malignant hypertension, in Cyp1a1-Ren2 transgenic rats.
Topics: Adrenal Glands; Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; | 2007 |
Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1).
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Disease Models, Animal; | 2007 |
[Primary hyperaldosteronism with malignant hypertension].
Topics: Adenoma; Adrenal Gland Neoplasms; Adrenalectomy; Adult; Blood Pressure Determination; Female; Humans | 1973 |
Problems in therapy for the hypertensive patient.
Topics: Antihypertensive Agents; Blood Pressure; Carotid Sinus; Diuretics; Electric Stimulation; Ethacrynic | 1973 |
Idiopathic membranous nephropathy in children.
Topics: Adolescent; Age Factors; Aminohippuric Acids; Basement Membrane; Biopsy; Child; Child, Preschool; Cr | 1973 |
[Respective roles of hemodynamic or humoral factors and of hypotensive or salidiuretic drugs in the development of essential hypertension].
Topics: Adult; Chlorthalidone; Diet, Sodium-Restricted; Electrocardiography; Guanethidine; Humans; Hydrochlo | 1965 |
[Malignant arterial hypertension. Intensive treatment by acute sodium depletion and antihypertensive agents].
Topics: Adult; Antihypertensive Agents; Body Weight; Creatinine; Diet, Sodium-Restricted; Diuretics; Female; | 1972 |